BOTHELL, WA--(Marketwire - November 15, 2010) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported revised financial results for the third quarter and nine months ended September 30, 2010.
Subsequent to the Company's earnings release and investor call on November 10, the Company determined that it should revise its recording of approximately $0.9 million in severance costs and stock-based compensation relating to accounting for the acquisition of Cequent Pharmaceuticals. The stock-based compensation was previously reflected as purchase consideration and the severance costs were previously reflected as liabilities assumed in the business combination. The revised accounting will record these amounts as expenses in the third quarter. This revision did not increase liabilities and will have no additional impact on the Company's cash balance.
The effect was to increase the net loss to $8.3 million, or $0.39 per share, from the previously reported result of $7.4 million, or $0.35 per share, for the third quarter ended September 30, 2010. For the nine months ended September 30, 2010, the net loss increased to $21.9 million, or $1.45 per share, from the previously reported amount of $21.0 million, or $1.40 per share.
These revisions will be reflected in the Company's 10-Q for the third quarter ended September 30, 2010, which is being filed with the Securities and Exchange Commission today.
Attached is a revised financial table showing the adjusted financial results.
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Marina Biotech's pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Marina Biotech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.
MARINA BIOTECH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
Three Months Ended Nine Months Ended
September 30, September 30,
2009 2010 2009 2010
----------- ----------- ----------- -----------
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
License and other
revenue $ 64 $ 1,130 $ 14,524 $ 1,507
----------- ----------- ----------- -----------
Operating expenses:
Research and
development 3,319 7,500 11,775 14,936
Selling, general and
administrative 3,478 3,956 7,836 8,763
Restructuring 118 460 429 746
----------- ----------- ----------- -----------
Total operating
expenses 6,915 11,916 20,040 24,445
----------- ----------- ----------- -----------
Income (loss) from
operations (6,851) (10,786) (5,516) (22,938)
Other income (expense):
Interest income 1 --- 4 ---
Interest and other
expense --- (321) (311) (1,645)
Net gain on
settlement of
liabilities --- 29 654 29
Change in fair value
price adjustable
warrants (160) 2,806 (2,092) 2,691
----------- ----------- ----------- -----------
Net loss $ (7,010) $ (8,272) $ (7,261) $ (21,863)
=========== =========== =========== ===========
Basic and diluted net
loss per share:
Net loss per common
share -- basic and
diluted $ (0.69) $ (0.39) $ (0.80) $ (1.45)
=========== =========== =========== ===========
Shares used in computing
net loss per share --
basic and diluted 10,178 20,982 9,084 15,045
=========== =========== =========== ===========
December 31, September 30,
Selected Balance Sheet Data (In Thousands) 2009 2010
----------- -----------
(Unaudited) (Unaudited)
Cash
(includes restricted cash of $998 and
$1,157, respectively) $ 1,746 $ 2,104
Accounts Receivable, net 211 161
Property and Equipment and Other Assets 5,272 4,844
Goodwill and Intangible Assets --- 29,617
----------- -----------
Total Assets 7,229 36,726
=========== ===========
Notes Payable, net of Discount 317 ---
Fair Value Liability for Price Adjustable
Warrants 7,243 3,500
Deferred Taxes --- 8,085
----------- -----------
Other Liabilities 6,555 8,801
----------- -----------
Total Liabilities 14,115 20,386
=========== ===========
Accumulated Deficit (263,017) (284,880)
=========== ===========
